Enalapril versus losartan for adults with chronic kidney disease: A systematic review and meta‐analysis

He, Yuan-Mei; Li, Feng; Huo, Dongmei; Yang, Zhenhua; Liao, Yunhua

doi:10.1111/nep.12134

Cited by 19 publications

(11 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…25 Oxidative stress and inflammation play a major role in the development and progression of CKD and are, in part, mediated by the impaired activation of the cytoprotective transcription factor, nuclear factor-erythroid-2-related factor 2 (Nrf2).…”

Section: The Second Step Verificationmentioning

confidence: 99%

Metabolomic Signatures of Chronic Kidney Disease of Diverse Etiologies in the Rats and Humans

et al. 2016

View full text Add to dashboard Cite

Chronic kidney disease (CKD) has emerged as a major public health problems worldwide. It frequently progresses to end-stage renal disease which is related to very high cost and mortality. Novel biomarkers can provide insight into the novel mechanism, facilitate early detection and monitor progression of CKD and its response to therapeutic interventions. To identify potential biomarkers, we applied an UPLC-HDMS together with univariate and multivariate statistical analyses using plasma samples from patients with CKD of diverse etiologies (100 sera in discovery set and 120 sera in validation set) and two different rat models of CKD. Using comprehensive screening and validation workflow, we identified a panel of seven metabolites which were shared by all patients and animals regardless of the underlying cause of CKD. These included ricinoleic acid, stearic acid, cytosine, LPA(16:0), LPA(18:2), 3-methylhistidine, and argininic acid. The combination of these seven biomarkers enabled the discrimination of patients with CKD from healthy subjects with a sensitivity of 83.3% and a specificity of 96.7%. In addition, these biomarkers accurately reflected improvements in renal function in response to the therapeutic interventions. Our results indicated that the identified biomarkers may improve the diagnosis of CKD and provide a novel tool for monitoring of the progression of disease and response to treatment in CKD patients.

show abstract

Section: The Second Step Verificationmentioning

confidence: 99%

Metabolomic Signatures of Chronic Kidney Disease of Diverse Etiologies in the Rats and Humans

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Biomacromolecules, such as proteins and polysaccharides, have attracted more attention because of their biocompatibility and biodegradability . Enalapril is an angiotensin‐converting enzyme (ACE) inhibitor that is used to treat high blood pressure, diabetic nephropathy and some types of chronic heart failure, left ventricular dysfunction (LVD), and chronic renal failure ,. It has been proven to protect the function of the kidneys in hypertension, heart failure, and diabetes, and may be used in the absence of hypertension for its kidney protective effects .…”

Section: Introductionmentioning

confidence: 99%

Synthesis and Evaluation of Enalapril‐Loaded PVA/PMC Modified Magnetic Nanoparticles as a Novel Efficient Nano‐Carrier

2019

View full text Add to dashboard Cite

In the present study, the development of new Enalapril‐loaded adsorbent and evaluation of drug release was studied in vitro. Initially, Fe3O4 magnetic nanoparticles were synthesized via co‐precipitation method. Then, the mixture of polymers was deposited on the surface of the magnetic nanoparticles via radical polymerization in order to enhance the adsorption capacity of nanoparticles with biocompatible poly methylcellulose modified with polyvinyl alcohol. The equilibrium adsorption data magnetite nano‐sorbent were analyzed using Langmuir, Freundlich, and Temkin. The drug‐release study showed that 80% of Enalapril released in the simulated gastrointestinal environment for 18 hours. The samples and products analyzed by FTIR, elemental analysis, thermal gravimetric analysis (TGA) and scanning electron microscopy (SEM). Adsorption parameters such as pH, temperature and contact time were optimized, and Langmuir, Freundlich and Temkin's isotherms were studied for the drug adsorption mechanism. The release process of Enalapril studied in the simulated human digestive environment. The release profile of Enalapril has a very steep slope for 30 minutes in the simulated human gastric.

show abstract

“…Enalapril is a drug used to treat high blood pressure, Kidney diseases [2], diabetes and heart failure [3]. It was patented in 1978 and came into medical use in 1984 [4].…”

Section: Introductionmentioning

confidence: 99%

The effect of Enalapril drug on some histological aspects of testes tissue in the mature albino male mice

Moosa

Ali

2018

ijs

View full text Add to dashboard Cite

The study aimed to evaluate whether Enalapril has any effects on the testicular tissue of the albino male mice which received or did not receive treatment with Enalapril. Mature mice were divided into three groups: control group which fed with 0.1mg of normal saline, the second group was orally fed with 10 mg/Kg of Enalapril drug while the third group was fed with 20 mg/Kg of drug, one time a day for 30 successive days by using gavage tube (0.1ml). The histological sections were performed and the slides were examined using the light microscope. The present study result of light microscopic images of mice testes cross sections which treated with 20 mg/Kg of Enalapril showed coagulated necrosis on spermatogonia germ cells, stopping the maturation in testicular tissue and ischematic alternations. Furthermore, the group treated with 10 mg/Kg showed arresting of spermatozoa maturation, congestion of blood vessels and spreading of edema. In comparison with the control group which demonstrated normal interstitial tissue and absence of edema with spermatogenic maturation observing numerous spermatozoa within the tubule lumen. In conclusion, Enalapril might play a role in pathogenesis of testicular tissue and men infertility.

show abstract

Enalapril versus losartan for adults with chronic kidney disease: A systematic review and meta‐analysis

Abstract: Enalapril has similar effects to losartan on systemic blood pressure, renal function and serum UA in patients with CKD, but carries a higher risk of dry cough. Larger trials are required to evaluate the effects of these medications on clinical outcomes.

Cited by 19 publications

References 40 publications

Metabolomic Signatures of Chronic Kidney Disease of Diverse Etiologies in the Rats and Humans

Metabolomic Signatures of Chronic Kidney Disease of Diverse Etiologies in the Rats and Humans

Synthesis and Evaluation of Enalapril‐Loaded PVA/PMC Modified Magnetic Nanoparticles as a Novel Efficient Nano‐Carrier

The effect of Enalapril drug on some histological aspects of testes tissue in the mature albino male mice

Contact Info

Product

Resources

About